Search research articles
Contact Us
Filters
Showing results (151-160 of 170) with videos related to
Page
of 17
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2023
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Sonya Krishnan, Xingye Wu, Soyeon Kim, et al.
The New England Journal of Medicine
|
March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study
Nishi Suryavanshi, Matthew Murrill, Amita Gupta, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Lancet (London, England)
|
December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 4, 2019
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Amita Gupta, Susan Swindells, Soyeon Kim, et al.
The New England Journal of Medicine
|
October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
Diane V Havlir, Michelle A Kendall, Prudence Ive, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 19, 2018
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection
Salmaan Keshavjee, Farhana Amanullah, Adithya Cattamanchi, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 170) with videos related to
Sort By:
Page
of 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2023
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Sonya Krishnan, Xingye Wu, Soyeon Kim, et al.
The New England Journal of Medicine
|
March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 29, 2019
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study
Nishi Suryavanshi, Matthew Murrill, Amita Gupta, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Lancet (London, England)
|
December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 4, 2019
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease
Amita Gupta, Susan Swindells, Soyeon Kim, et al.
The New England Journal of Medicine
|
October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
Diane V Havlir, Michelle A Kendall, Prudence Ive, et al.
American Journal of Respiratory and Critical Care Medicine
|
October 19, 2018
Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection
Salmaan Keshavjee, Farhana Amanullah, Adithya Cattamanchi, et al.
American Journal of Respiratory and Critical Care Medicine
|
February 15, 2023
A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials
Ekaterina V Kurbatova, Patrick P J Phillips, Susan E Dorman, et al.
Page
of 17